Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 59 of 404 for:    PYY

Role of Acute Exercise Modality on Appetite Regulation and Energy Intake

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03143868
Recruitment Status : Completed
First Posted : May 8, 2017
Last Update Posted : June 4, 2019
Sponsor:
Collaborator:
National Center for Advancing Translational Science (NCATS)
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:

This study plans to learn more about how type of exercise influences measures of appetite regulation. In this study, investigators will be evaluating a resistance exercise session (using weight machines and free weights) and an aerobic exercise session (using a treadmill). Participants will also complete a sedentary control condition.

A secondary purpose is to compare sex-based differences in appetite-indices in response to exercise. Therefore, the responses to aerobic and resistance exercise will also be compared between men and women.


Condition or disease Intervention/treatment Phase
Appetite Regulation Acute Exercise Energy Intake Behavioral: Exercise Modality Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 38 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Role of Acute Exercise Modality on Appetite Regulation and Energy Intake
Actual Study Start Date : June 14, 2017
Actual Primary Completion Date : June 3, 2019
Actual Study Completion Date : June 3, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Aerobic Exercise Behavioral: Exercise Modality
The overall aim of this study is to compare how acute exercise modality (e.g. resistance exercise vs. aerobic exercise) differentially influence hormonal and behavioral indices of appetite regulation and ad libitum energy intake. Both conditions will also be compared to a non-exercise control condition.

Experimental: Resistance Exercise Behavioral: Exercise Modality
The overall aim of this study is to compare how acute exercise modality (e.g. resistance exercise vs. aerobic exercise) differentially influence hormonal and behavioral indices of appetite regulation and ad libitum energy intake. Both conditions will also be compared to a non-exercise control condition.

Placebo Comparator: No Exercise Behavioral: Exercise Modality
The overall aim of this study is to compare how acute exercise modality (e.g. resistance exercise vs. aerobic exercise) differentially influence hormonal and behavioral indices of appetite regulation and ad libitum energy intake. Both conditions will also be compared to a non-exercise control condition.




Primary Outcome Measures :
  1. Change in Ghrelin Area Under the Curve (AUC) [ Time Frame: At baseline and every 30 minutes for 3 hours following a breakfast meal ]
    Concentration of ghrelin values, overtime for each arm of the study

  2. Change in Peptide YY (PYY) AUC [ Time Frame: At baseline and every 30 minutes for 3 hours following a breakfast meal ]
    Concentration of PYY values, overtime for each arm of the study

  3. Change in GLP-1 AUC [ Time Frame: At baseline and every 30 minutes for 3 hours following a breakfast meal ]
    Concentration of GLP-1 values, overtime for each arm of the study. Added in December 2017 following receipt of additional funding to add this measure)


Secondary Outcome Measures :
  1. Change in Hunger AUC [ Time Frame: At baseline and every 30 minutes for 3 hours following a breakfast meal ]
    Subjective indicator of hunger values, overtime for each arm of the study. Evaluated via 100 mm visual analogue scales

  2. Change in Satiety AUC [ Time Frame: At baseline and every 30 minutes for 3 hours following a breakfast meal ]
    Subjective indicator of satiety values, overtime for each arm of the study. Evaluated via 100 mm visual analogue scales

  3. Change in Prospective Food Consumption AUC [ Time Frame: At baseline and every 30 minutes for 3 hours following a breakfast meal ]
    Subjective indicator of prospective food consumption values, overtime for each arm of the study. Evaluated via 100 mm visual analogue scales

  4. Change in Ad libitum Energy Intake - in lab [ Time Frame: 3 hours following breakfast meal on each arm ]
    In lab ad libitum buffet lunch (via weigh and measure methodology) at the end of each study arm visit

  5. Change in Ad libitum Energy Intake - free living [ Time Frame: For 3 days following each arm ]
    3 days of free-living ad libitum energy intake (via self-report)


Other Outcome Measures:
  1. Difference Between Men and Women in Appetite-Indices [ Time Frame: At baseline, every 30 minutes for 3 hours following a breakfast meal, and for 3 days following each arm ]
    Sex-Based Differences (Added in December 2017 following receipt of additional funding to increase sample size for this purpose)

  2. Difference in Behavioral Economics Constructs (Delayed Discounting and Hypothetical Purchase Task) [ Time Frame: In the fed state, following completion of assigned exercise bout (or control bout). ]
    Delayed Discounting to evaluate value of future outcomes. Hypothetical Purchase Task to evaluate value of food. (Added in December 2017 following meeting with a colleague interested in adding these measures)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • All ethnic groups and both genders
  • Age: 18-55 yrs (changed in September 2018 because trial we are modeling enrollment criteria on [NCT02047721] changed age range, so we adjusted for this trial as well)
  • BMI: 18.5-40 kg/m2 (changed in June 2018 from original range of 27-35 kg/m2 in order to improve recruitment. This is because recruitment within our prior BMI range had been slower than anticipated and potential participants that have expressed interest have screened out because of this. Given that we are still limiting enrollment criteria to adults who are inactive, it is likely that most will have body fat levels above normative standards, and therefore still be classified as having excess adiposity, even if their BMI is below 25 kg/m2. Furthermore, given the pilot nature of this work we believe it is important to complete the trial in a timely manner. We anticipate alterations to the enrollment criteria helping with this effort.)
  • Weight stable within ±5% in the last 6 months
  • Physically inactive (not meeting current physical activity guidelines, by self-report, no resistance training in previous 12-months)

Exclusion Criteria:

  • History of cardiovascular disease (CVD), diabetes mellitus, uncontrolled hypertension (defined as: systolic blood pressure >160 mmHg or diastolic blood pressure >100mmHg, as measured during the screening visit with participants seated quietly, following established guidelines39), renal disease (e.g. chronic kidney disease, polycystic kidney disease, nephritis, etc.), hepatic disease (e.g. cirrhosis, liver failure, fatty liver, jaundice, etc.), untreated thyroid disease (e.g. Grave's disease, Hashimoto's disorder, goiters, thyroid cancers, etc.), or any other medical condition affecting weight or energy metabolism. Participants who are deemed ineligible based upon uncontrolled hypertension criteria will be referred to their primary care physicians for treatment. If this conditions become controlled they will be allowed to be re-evaluated for inclusion in the current trial.
  • Symptoms suggestive of CVD: chest pain, shortness of breath at rest or with mild exertion, syncope.
  • Unable to exercise due to cardiac, pulmonary, neurologic or orthopedic reasons.
  • Significant gastrointestinal disorders including: inflammatory bowel disease requiring treatment within the past year, chronic malabsorptive conditions, chronic diarrhea, or active gallbladder disease.
  • Currently smoking and/or nicotine use within the past 6 months.
  • Treatment with medications known to significantly affecting appetite, weight, energy metabolism, energy intake or energy expenditure in the last 6 months (e.g. systemic corticosteroids, appetite suppressants, lithium, stimulants, anti-psychotics, tricyclic antidepressants).
  • Weight loss or weight gain of >5% in past 6 months.
  • History of surgical procedure for weight loss at any time (e.g. gastroplasty, gastric bypass, gastrectomy or partial gastrectomy, adjustable banding, gastric sleeve); history of extensive bowel resection for other reasons.
  • Currently pregnant (confirmed via urine pregnancy test), lactating or less than 6 months post-partum.
  • Self-report of alcohol or substance abuse within the past 12 months.
  • History of clinically diagnosed eating disorders including anorexia nervosa, bulimia, binge eating disorder, or score >20 on the EATS-26. Participants with a score >20 on the EATS-26 will be referred to their primary care physician for further evaluation.
  • Major psychiatric disorder (e.g. diagnosis of schizophrenia, bipolar disorder, or other psychotic disorders).
  • Current severe depression or history of severe depression within the previous year (based on reported history, study physician examination findings, and/or a score >21 on the CES-D). Participants meeting any of these criteria will be referred to their primary care physician and/or the emergency department (based upon study physician determined level of severity).
  • Significant food intolerances/allergies that cannot be accommodated by the CTRC Metabolic Kitchen.
  • Currently participating in or planning to participate in any formal weight loss or physical activity programs or clinical trials.
  • Other medical, psychiatric, or behavioral limitations that may interfere with participation (as determined by study physician).
  • Unable or unwilling to undergo study procedures
  • Women who are peri- or post-menopausal, or report irregular menstrual cycles.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03143868


Locations
Layout table for location information
United States, Colorado
University of Colorado Denver - Anschutz Medical Campus
Aurora, Colorado, United States, 80045
Sponsors and Collaborators
University of Colorado, Denver
National Center for Advancing Translational Science (NCATS)
Investigators
Layout table for investigator information
Principal Investigator: Tanya M Halliday, PhD, RD University of Colorado, Denver

Layout table for additonal information
Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT03143868     History of Changes
Other Study ID Numbers: 16-2697
UL1TR001082-04 ( U.S. NIH Grant/Contract )
First Posted: May 8, 2017    Key Record Dates
Last Update Posted: June 4, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Colorado, Denver:
acute exercise
resistance exercise
aerobic exercise
appetite
energy intake